Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Gamma Interferon in Friedreich Ataxia
NCT03888664Phase 2Completed
- Sponsor
- IRCCS Eugenio Medea
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, open-label, single-arm trial of interferon gamma-1b in Friedreich ataxia (FA), sponsored by IRCCS Eugenio Medea. Primary endpoint: Number and severity of adverse drug reactions at 12 months. Started Jun 2016; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT03888664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888664.